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9A recent article suggested that screening for abdominal
aortic aneurysm (AAA) might cause more harm than good.
Johansson et al.1 reported that if 10,000 men were invited
for screening, 46 AAA deaths would be prevented over 13e
15 years, but 176 men would have a small aneurysm
(greater than 3 cm) diagnosed that would never require
treatment. According to Johansson, this second group are
said to be “overdiagnosed,” incurring a risk of psychological
morbidity2 without the beneﬁt of a reduced risk of AAA-
related mortality. The concept of overdiagnosis is impor-
tant. Its basis lies in the debatable balance between beneﬁt
and harm that remains central to healthcare ethics; how-
ever, a precise deﬁnition is lacking. Johansson suggests that
for AAA, anyone (following screening) who is diagnosed
with an aneurysm that would never have caused any
symptoms (or death) should be deﬁned as being over-
diagnosed, and that this represents the “most serious
harm.”
Central to this issue is the balance of illness/preventable
death and quality of life. Five observational studies2e6 have
investigated quality of life (QoL) in those who are screened
positive for AAA, with one reporting short-term decreases
in QoL at 1 year and four demonstrating no clinically
important decrease in QoL in those screened positive
compared with an unscreened control group. It is plausible
that some patients are heavily burdened by a positive
diagnosis; however, it should also be considered that many
patients are reassured by a negative screen result while
others may see a diagnosis of a 3e5.5 cm AAA as an op-
portunity to treat a life threatening disease that may
otherwise have been missed. Patients decide whether or
not to attend their screening appointment and current ev-
idence does not point towards excess psychosocial harm
from screening, although further studies utilising AAA-
speciﬁc quality of life instruments are needed.
Preventing “illness” is equally important to the balance of
overdiagnosis. A systematic review for the U.S. Preventive
Services Task Force7 concluded that AAA screening in men
aged 65 years or older was associated with decreased AAA
rupture and AAA-related mortality rates, but had little ef-
fect on all-cause mortality. In contrast, Lindholt et al.8
examined the pooled effects of AAA screening on all-
cause mortality, ﬁnding a signiﬁcant reduction in mortality
(OR 0.94, 95% CI 0.92e0.97), while the 13-year follow-up1078-5884/ 2015 European Society for Vascular Surgery. Published by
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http://dx.doi.org/10.1016/j.ejvs.2015.06.001from the Multicentre Aneurysm Screening Study (MASS)
reported an overall reduction in all-cause mortality of 3%.
AAA screening may therefore reduce both aneurysm and
all-cause mortality.
Causes of non-aneurysm death were addressed within
the MASS trial9 which demonstrated similar causes of death
in the invited and control groups, chieﬂy from ischaemic
heart disease (8.7% vs. 9.0%, respectively), stroke (2.7% for
both), and cancer (14.0% vs. 14.1%, respectively). An early
diagnosis of AAA (through screening) is increasingly being
recognised as an important marker of cardiovascular risk
giving screened patients the opportunity to modify their
risk of heart disease10 and stroke through the best medical
therapy, smoking cessation, weight loss, and regular exer-
cise. Furthermore, new therapeutic agents, such as PCSK9
or P2Y12 inhibitors, have the potential to improve the
effectiveness of secondary cardiovascular prevention stra-
tegies and further improve the health of patients with a
small AAA. This would increase the beneﬁts of early diag-
nosis, irrespective of whether a patient ultimately requires
an AAA repair or not. Therefore, up-to-date studies
regarding the effect of AAA screening on all-cause mortality
may reﬂect these improvements in overall care.
Fundamental to the risk of overdiagnosis raised by
Johansson is unnecessary preventive surgery. Those authors
estimate that if 94 men did not have surgery for their
screen proven AAA, 57 would have ruptured, from which 44
would have died. Thus 37 (95% CI 15e60) had “unnec-
essary” preventive surgery. Predicting those aneurysms that
will rupture is not currently achievable, and such a strategy
would place patients at unacceptable risk. The potential
risks of surgery can, however, be reduced. In the UK, an AAA
Quality Improvement Programme was implemented in 2008
which reduced mortality rates following elective AAA repair
from 7% to 2.4% by 2013.11 Present mortality may be lower
than 1%.12,13 Current practice is to consider intervention on
aneurysms of 5.5 cm or greater (screened or un-screened)
and there is no evidence that the risk of rupture at
5.5 cm has been affected by risk factor modiﬁcation.
Risk factor modiﬁcation has, however, likely played a part
in the declining prevalence of AAA. Johansson highlights the
important issue of cost-effectiveness of AAA screening
within this changing epidemiology, but fails to acknowledge
the latest evidence in this area. Utilising long-term data
from MASS, Glover et al.14 demonstrated that (despite
increased costs and a lower prevalence), AAA screening in
the UK remained highly cost-effective, with similar ﬁndings
published by Svensjö et al.15 in Sweden.
410 EditorialCuriously, Johansson et al. suggest that a screening pro-
gramme “doubles” the prevalence of AAA. The screening
program exists to identify people with aneurysmal aortas
who were previously “unknown” and, although this does
not increase the number of people with aneurysms, it does
increase the number of which we are aware. Finally, the
authors raise concern over the debate to include sub-
aneurysmal aortic dilation (2.5e2.9 cm) within the
screening program. Although there is evidence16 that some
of these patients may progress to develop an aneurysm at
10 years, it remains unclear whether these patients would
beneﬁt from a modiﬁed form of surveillance; for example
with a repeat scan at 70 years.13
The deﬁnition of “overdiagnosis” in AAA remains to be
established and careful discussion is required among clini-
cians, decision-makers, and patients to ﬁnd the correct
balance. In an effort to ﬁnd clinically relevant AAA, it is
likely that a number of patients are found whose aneurysms
will not develop or cause future symptoms; however, we
would argue that the most serious harm comes not from
overdiagnosis, but from exposing patients to the life-
threatening consequences of aneurysm rupture when this
could have been prevented.
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